[Antioxidant and metabolic therapy of lower limb chronic obliterative arterial disease].
Metabolic therapy is one of several therapeutic strategies that can be used in patients with lower limb chronic obliterative arterial disease (COAD). Tanakan (EGb76) has demonstrated high efficiency and safety in 9 controlled clinical trials and author's clinical series in patients with lower limb COAD. Improvement with significant increase of pain-free walking distance and beneficial safety profile was observed in all cases. Tanakan (EGb76) is highly effective conventional therapeutic agent for memory and attention disorders, dizziness and balance disturbances in adults and elderly patients. Given a common concomitance of these disorders and lower limb COAD, Tanakan can be recommended as a drug of choice for treatment of chronic obliterative arteriopathy.
Koshkin
V M
VM
Faculty Surgery Clinics, Russian State Medical University, Moscow, Russia.
Murav'ev
S V
SV
Dadova
L V
LV
Kalashov
P B
PB
D000975:Antioxidants / Q000627:therapeutic use*; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy* / Q000503:physiopathology*; D050197:Atherosclerosis; D002908:Chronic Disease; D020441:Ginkgo biloba; D006801:Humans; D035002:Lower Extremity / Q000098:blood supply*; D010936:Plant Extracts / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D000096983:Ginkgo Extract
D000975:Antioxidants; D010936:Plant Extracts; D014665:Vasodilator Agents; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract